Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older and in good health (Investigator discretion) with a recent stable medical history~* Met American College of Rheumatology (ACR) criteria for diagnosis of active rheumatoid arthritis (RA) and had at both screening and baseline visits \>=6 swollen joints and \>=9 tender joints, despite a minimum of 3-months treatment with methotrexate (MTX). (Distal interphalangeal joints \[DIPs\] were not to be included in joint count for inclusion. The screening and baseline visits could be 3 to 28 days apart for patients not previously receiving disease-modifying anti-rheumatic drugs \[DMARDs\] other than MTX or 4 to 6 weeks for patients requiring a DMARD washout period.)~* Insufficient efficacy with MTX 12.5 to 25 mg per week (10 mg per week if MTX intolerant).~* If patient on a second-line treatment (DMARD) other than MTX, he/she had to discontinue it for at least 28 days before the baseline visit (the washout period).~* Treatment with oral folic acid 1-3 mg/day or, if appropriate, up to 10 mg leucovorin per week.~* Both rheumatoid factor positivity and a C-reactive protein value \>=1 mg/dL, or at least one joint erosion on X-ray.~Exclusion Criteria:~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study.~* Female subject who was pregnant or breast-feeding or considering becoming pregnant.~* Preceding treatment with any tumor necrosis factor (TNF) antagonist, including adalimumab.~* Prior exposure to alkylating agents, such as chlorambucil or cyclophosphamide.~* Intra-articular, intramuscular, or intravenous administration of corticosteroids within 4 weeks prior to the screening visit.~* Subject was wheelchair bound or bedridden.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DB adalimumab 20 mg ew (Type: EXPERIMENTAL): Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
- DB adalimumab 40 mg eow (Type: EXPERIMENTAL): Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
- DB placebo ew (Type: PLACEBO_COMPARATOR): Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
- DB adalimumab 20 mg ew/OL adalimumab 40 mg eow (Type: EXPERIMENTAL): Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
- DB adalimumab 40 mg eow/OL adalimumab 40 mg eow (Type: EXPERIMENTAL): Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
- DB placebo ew/OL adalimumab 40 mg eow (Type: EXPERIMENTAL): Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).

Based on this trial design, predict the completion outcome and termination type (if applicable).